Michael James Hassett, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 63 | 2024 | 21187 | 2.550 |
Why?
|
Breast Neoplasms, Male | 5 | 2024 | 212 | 2.310 |
Why?
|
Medical Oncology | 14 | 2024 | 2350 | 1.680 |
Why?
|
Neoplasms | 29 | 2025 | 22390 | 1.660 |
Why?
|
Neoplasm Recurrence, Local | 19 | 2021 | 9442 | 1.640 |
Why?
|
Electronic Health Records | 12 | 2024 | 4879 | 1.220 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 9 | 2020 | 933 | 1.180 |
Why?
|
Mastectomy, Segmental | 9 | 2021 | 960 | 0.910 |
Why?
|
Neoplasm Staging | 26 | 2024 | 11262 | 0.910 |
Why?
|
Colorectal Neoplasms | 8 | 2023 | 6982 | 0.870 |
Why?
|
Cancer Care Facilities | 2 | 2024 | 428 | 0.840 |
Why?
|
Health Care Costs | 6 | 2021 | 3270 | 0.830 |
Why?
|
Lung Neoplasms | 11 | 2021 | 13593 | 0.760 |
Why?
|
Clinical Coding | 3 | 2018 | 187 | 0.680 |
Why?
|
Off-Label Use | 1 | 2022 | 185 | 0.680 |
Why?
|
Medication Errors | 2 | 2018 | 784 | 0.650 |
Why?
|
Insurance Claim Review | 3 | 2018 | 746 | 0.610 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 11886 | 0.610 |
Why?
|
Neoplasms, Second Primary | 2 | 2018 | 1060 | 0.570 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2020 | 1093 | 0.560 |
Why?
|
Patients | 1 | 2023 | 908 | 0.560 |
Why?
|
Receptors, Estrogen | 7 | 2024 | 2252 | 0.540 |
Why?
|
Chemotherapy, Adjuvant | 13 | 2024 | 3554 | 0.540 |
Why?
|
SEER Program | 12 | 2024 | 1473 | 0.530 |
Why?
|
Antineoplastic Agents | 11 | 2018 | 13699 | 0.520 |
Why?
|
Mastectomy | 5 | 2021 | 1850 | 0.510 |
Why?
|
Receptor, erbB-2 | 6 | 2022 | 2606 | 0.480 |
Why?
|
Molecular Targeted Therapy | 5 | 2024 | 2830 | 0.470 |
Why?
|
Patient Care Management | 1 | 2017 | 304 | 0.460 |
Why?
|
Humans | 115 | 2025 | 768887 | 0.450 |
Why?
|
Quality of Life | 7 | 2024 | 13510 | 0.430 |
Why?
|
International Classification of Diseases | 1 | 2019 | 936 | 0.420 |
Why?
|
Female | 79 | 2025 | 397464 | 0.420 |
Why?
|
Algorithms | 6 | 2019 | 14199 | 0.400 |
Why?
|
Electronic Prescribing | 1 | 2012 | 115 | 0.380 |
Why?
|
Artificial Intelligence | 3 | 2024 | 2665 | 0.370 |
Why?
|
Medical Order Entry Systems | 2 | 2013 | 523 | 0.370 |
Why?
|
Unnecessary Procedures | 1 | 2014 | 419 | 0.360 |
Why?
|
Fee-for-Service Plans | 2 | 2017 | 714 | 0.350 |
Why?
|
Software | 2 | 2023 | 4480 | 0.350 |
Why?
|
Healthcare Disparities | 5 | 2022 | 3421 | 0.340 |
Why?
|
Research Design | 5 | 2023 | 6213 | 0.320 |
Why?
|
Breast | 6 | 2023 | 1976 | 0.320 |
Why?
|
Quality of Health Care | 4 | 2018 | 4338 | 0.310 |
Why?
|
Middle Aged | 43 | 2025 | 223740 | 0.310 |
Why?
|
Medicare | 11 | 2022 | 6888 | 0.310 |
Why?
|
United States | 26 | 2022 | 73180 | 0.310 |
Why?
|
Drug Interactions | 1 | 2013 | 1421 | 0.310 |
Why?
|
Aged | 37 | 2025 | 171790 | 0.300 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3709 | 0.290 |
Why?
|
Prognosis | 14 | 2024 | 30044 | 0.280 |
Why?
|
Safety Management | 1 | 2012 | 765 | 0.270 |
Why?
|
Telemedicine | 2 | 2021 | 3109 | 0.270 |
Why?
|
Combined Modality Therapy | 7 | 2022 | 8559 | 0.270 |
Why?
|
Anti-Anxiety Agents | 1 | 2008 | 405 | 0.260 |
Why?
|
Health Priorities | 1 | 2008 | 380 | 0.250 |
Why?
|
Registries | 8 | 2023 | 8384 | 0.240 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1812 | 0.230 |
Why?
|
Quality Improvement | 2 | 2017 | 3856 | 0.230 |
Why?
|
Cyclophosphamide | 2 | 2020 | 2227 | 0.230 |
Why?
|
Male | 28 | 2025 | 365249 | 0.220 |
Why?
|
Genetic Testing | 4 | 2020 | 3590 | 0.220 |
Why?
|
Electronics | 2 | 2022 | 317 | 0.220 |
Why?
|
Quality Assurance, Health Care | 1 | 2014 | 2181 | 0.220 |
Why?
|
Doxorubicin | 2 | 2020 | 2234 | 0.210 |
Why?
|
Cohort Studies | 12 | 2024 | 41800 | 0.210 |
Why?
|
Medicaid | 2 | 2015 | 2843 | 0.210 |
Why?
|
Health Status Indicators | 3 | 2018 | 971 | 0.210 |
Why?
|
Employment | 1 | 2009 | 1114 | 0.210 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2023 | 101 | 0.200 |
Why?
|
Adult | 28 | 2025 | 223818 | 0.200 |
Why?
|
Hemangiosarcoma | 1 | 2024 | 215 | 0.190 |
Why?
|
Age Factors | 6 | 2025 | 18454 | 0.190 |
Why?
|
Nausea | 1 | 2024 | 682 | 0.190 |
Why?
|
Health Expenditures | 4 | 2018 | 2396 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2022 | 10397 | 0.180 |
Why?
|
Cost-Benefit Analysis | 5 | 2022 | 5544 | 0.170 |
Why?
|
Gene Expression Profiling | 3 | 2020 | 9549 | 0.170 |
Why?
|
Receptors, Progesterone | 3 | 2020 | 1159 | 0.170 |
Why?
|
Filgrastim | 1 | 2020 | 131 | 0.170 |
Why?
|
Treatment Outcome | 13 | 2020 | 65485 | 0.170 |
Why?
|
Technology Assessment, Biomedical | 1 | 2022 | 312 | 0.170 |
Why?
|
Survivors | 1 | 2010 | 2383 | 0.170 |
Why?
|
Psychotherapy | 1 | 2008 | 1654 | 0.170 |
Why?
|
Constipation | 1 | 2024 | 570 | 0.160 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2020 | 878 | 0.160 |
Why?
|
Databases, Factual | 4 | 2018 | 8095 | 0.160 |
Why?
|
Medical Audit | 2 | 2018 | 454 | 0.160 |
Why?
|
Mouth Neoplasms | 1 | 2023 | 597 | 0.150 |
Why?
|
Drug Administration Routes | 1 | 2018 | 151 | 0.150 |
Why?
|
Time Factors | 10 | 2024 | 40266 | 0.150 |
Why?
|
Natural Language Processing | 3 | 2021 | 1203 | 0.150 |
Why?
|
Caregivers | 1 | 2010 | 2308 | 0.150 |
Why?
|
Delivery of Health Care | 3 | 2024 | 5375 | 0.150 |
Why?
|
Research Report | 1 | 2021 | 369 | 0.150 |
Why?
|
Aged, 80 and over | 11 | 2025 | 59738 | 0.140 |
Why?
|
Health Status Disparities | 1 | 2009 | 1886 | 0.140 |
Why?
|
Neoadjuvant Therapy | 3 | 2022 | 2909 | 0.140 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1737 | 0.140 |
Why?
|
Carboplatin | 1 | 2020 | 799 | 0.140 |
Why?
|
Endpoint Determination | 1 | 2019 | 594 | 0.140 |
Why?
|
Insurance Carriers | 1 | 2018 | 159 | 0.130 |
Why?
|
Proportional Hazards Models | 5 | 2023 | 12563 | 0.130 |
Why?
|
Antidepressive Agents | 1 | 2008 | 2914 | 0.130 |
Why?
|
Insurance, Health | 1 | 2008 | 2518 | 0.130 |
Why?
|
Markov Chains | 1 | 2020 | 979 | 0.130 |
Why?
|
Hypopituitarism | 1 | 1998 | 252 | 0.130 |
Why?
|
Drug Prescriptions | 2 | 2018 | 1673 | 0.130 |
Why?
|
Prostatic Neoplasms | 3 | 2017 | 11229 | 0.130 |
Why?
|
Paclitaxel | 2 | 2021 | 1735 | 0.130 |
Why?
|
Genetic Counseling | 1 | 2020 | 634 | 0.130 |
Why?
|
Delphi Technique | 1 | 2020 | 890 | 0.130 |
Why?
|
Risk Assessment | 6 | 2024 | 24330 | 0.120 |
Why?
|
Mammography | 2 | 2020 | 2434 | 0.120 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2025 | 1106 | 0.120 |
Why?
|
Axilla | 1 | 2018 | 625 | 0.120 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2023 | 957 | 0.120 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1398 | 0.120 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20244 | 0.120 |
Why?
|
Hospitalization | 4 | 2023 | 10845 | 0.120 |
Why?
|
Risk Management | 1 | 2018 | 558 | 0.120 |
Why?
|
Mass Screening | 1 | 2010 | 5455 | 0.120 |
Why?
|
Hernia, Diaphragmatic | 1 | 1995 | 244 | 0.120 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1197 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2013 | 1535 | 0.110 |
Why?
|
Carcinoma in Situ | 1 | 2020 | 788 | 0.110 |
Why?
|
Models, Statistical | 3 | 2020 | 5107 | 0.110 |
Why?
|
Mastectomy, Modified Radical | 1 | 2013 | 62 | 0.110 |
Why?
|
New York | 1 | 2015 | 884 | 0.110 |
Why?
|
Decision Support Techniques | 2 | 2020 | 2008 | 0.110 |
Why?
|
Cost Savings | 1 | 2018 | 915 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 5434 | 0.100 |
Why?
|
Self Report | 1 | 2024 | 3773 | 0.100 |
Why?
|
Odds Ratio | 5 | 2021 | 9682 | 0.100 |
Why?
|
Economics, Pharmaceutical | 1 | 2012 | 88 | 0.100 |
Why?
|
Palliative Care | 3 | 2025 | 3644 | 0.100 |
Why?
|
Tumor Burden | 1 | 2018 | 1913 | 0.100 |
Why?
|
Early Detection of Cancer | 2 | 2020 | 3238 | 0.100 |
Why?
|
Data Collection | 1 | 2021 | 3322 | 0.100 |
Why?
|
Health Maintenance Organizations | 1 | 2014 | 657 | 0.100 |
Why?
|
Decision Support Systems, Clinical | 1 | 2021 | 1177 | 0.100 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1273 | 0.100 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39394 | 0.090 |
Why?
|
Radiosurgery | 1 | 2021 | 1346 | 0.090 |
Why?
|
California | 1 | 2015 | 1443 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2022 | 2784 | 0.090 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15471 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2020 | 2460 | 0.090 |
Why?
|
Logistic Models | 4 | 2016 | 13317 | 0.090 |
Why?
|
Postoperative Complications | 2 | 2012 | 15889 | 0.090 |
Why?
|
Consensus | 1 | 2020 | 3214 | 0.080 |
Why?
|
Retrospective Studies | 9 | 2024 | 81892 | 0.080 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2012 | 410 | 0.080 |
Why?
|
Communication | 1 | 2023 | 3908 | 0.080 |
Why?
|
Aromatase Inhibitors | 1 | 2012 | 519 | 0.080 |
Why?
|
Tamoxifen | 1 | 2013 | 967 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 36861 | 0.080 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3629 | 0.080 |
Why?
|
Hospital Costs | 1 | 2014 | 959 | 0.080 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2021 | 3411 | 0.070 |
Why?
|
Disease-Free Survival | 3 | 2023 | 6856 | 0.070 |
Why?
|
Delayed Diagnosis | 1 | 2011 | 468 | 0.070 |
Why?
|
Risk Factors | 6 | 2018 | 74971 | 0.070 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 4926 | 0.070 |
Why?
|
Collagen | 1 | 1995 | 2646 | 0.070 |
Why?
|
Liver Neoplasms | 1 | 2023 | 4363 | 0.070 |
Why?
|
Drug Utilization | 1 | 2012 | 1191 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8512 | 0.070 |
Why?
|
Practice Guidelines as Topic | 3 | 2024 | 7460 | 0.070 |
Why?
|
Severity of Illness Index | 1 | 2024 | 15955 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2017 | 1793 | 0.070 |
Why?
|
Drug Industry | 1 | 2012 | 793 | 0.060 |
Why?
|
Evaluation Studies as Topic | 1 | 2008 | 1629 | 0.060 |
Why?
|
Prospective Studies | 6 | 2021 | 54950 | 0.060 |
Why?
|
Benchmarking | 1 | 2012 | 1058 | 0.060 |
Why?
|
Forecasting | 1 | 2014 | 2946 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3538 | 0.060 |
Why?
|
Incidence | 2 | 2024 | 21545 | 0.060 |
Why?
|
Carcinoma, Lobular | 1 | 2009 | 480 | 0.060 |
Why?
|
Administration, Oral | 1 | 2012 | 4042 | 0.060 |
Why?
|
Mammaplasty | 2 | 2013 | 1263 | 0.060 |
Why?
|
Patient Participation | 1 | 2013 | 1448 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6546 | 0.060 |
Why?
|
Biopsy, Needle | 1 | 2009 | 1627 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3608 | 0.060 |
Why?
|
Psychotic Disorders | 1 | 1998 | 3279 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 8055 | 0.050 |
Why?
|
Decision Making | 2 | 2013 | 3952 | 0.050 |
Why?
|
Lung | 2 | 2020 | 10097 | 0.050 |
Why?
|
Premedication | 1 | 2021 | 246 | 0.050 |
Why?
|
Lymphatic Metastasis | 1 | 2008 | 2916 | 0.040 |
Why?
|
Menopause | 1 | 2008 | 1656 | 0.040 |
Why?
|
Empirical Research | 1 | 2020 | 119 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2010 | 2240 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2021 | 9213 | 0.040 |
Why?
|
Computer Simulation | 1 | 2013 | 6289 | 0.040 |
Why?
|
Massachusetts | 1 | 2012 | 8888 | 0.040 |
Why?
|
Regression Analysis | 1 | 2008 | 6346 | 0.040 |
Why?
|
Patient Admission | 1 | 2006 | 1369 | 0.040 |
Why?
|
Communication Barriers | 1 | 2022 | 419 | 0.040 |
Why?
|
Biomedical Technology | 1 | 2021 | 210 | 0.040 |
Why?
|
Selection Bias | 1 | 2020 | 360 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2238 | 0.040 |
Why?
|
Regional Health Planning | 1 | 2018 | 96 | 0.040 |
Why?
|
Adolescent | 3 | 2012 | 89247 | 0.040 |
Why?
|
Policy | 1 | 2022 | 514 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 620 | 0.040 |
Why?
|
Young Adult | 3 | 2020 | 60110 | 0.040 |
Why?
|
Insurance Coverage | 1 | 2008 | 1946 | 0.040 |
Why?
|
Minority Groups | 1 | 2024 | 1216 | 0.030 |
Why?
|
Patient-Centered Care | 2 | 2020 | 1447 | 0.030 |
Why?
|
Hydroxyproline | 1 | 1995 | 110 | 0.030 |
Why?
|
World Health Organization | 1 | 2022 | 1327 | 0.030 |
Why?
|
Venules | 1 | 1995 | 161 | 0.030 |
Why?
|
Survival Rate | 2 | 2020 | 12873 | 0.030 |
Why?
|
Lung Compliance | 1 | 1995 | 207 | 0.030 |
Why?
|
Physicians | 1 | 2013 | 4607 | 0.030 |
Why?
|
Persistent Fetal Circulation Syndrome | 1 | 1995 | 80 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2009 | 7860 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2231 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26384 | 0.030 |
Why?
|
Pulmonary Surfactants | 1 | 1995 | 169 | 0.030 |
Why?
|
Arterioles | 1 | 1995 | 252 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2016 | 300 | 0.030 |
Why?
|
Primary Health Care | 1 | 2011 | 4748 | 0.030 |
Why?
|
Elastin | 1 | 1995 | 299 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2018 | 737 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2011 | 22294 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 820 | 0.030 |
Why?
|
Sheep | 1 | 1995 | 1451 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9264 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2023 | 5323 | 0.020 |
Why?
|
Medical Record Linkage | 1 | 2013 | 286 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1672 | 0.020 |
Why?
|
Bronchi | 1 | 1995 | 850 | 0.020 |
Why?
|
Poverty | 1 | 2023 | 2720 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2339 | 0.020 |
Why?
|
Sex Factors | 1 | 2025 | 10641 | 0.020 |
Why?
|
Genes, erbB-2 | 1 | 2011 | 162 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8742 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2015 | 12093 | 0.020 |
Why?
|
Inappropriate Prescribing | 1 | 2012 | 212 | 0.020 |
Why?
|
Health Promotion | 1 | 2022 | 2210 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4265 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 714 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10115 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5707 | 0.020 |
Why?
|
Prevalence | 1 | 2025 | 15875 | 0.020 |
Why?
|
Propensity Score | 1 | 2015 | 1968 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5928 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2006 | 7956 | 0.020 |
Why?
|
Gestational Age | 1 | 1995 | 3610 | 0.020 |
Why?
|
Intestines | 1 | 1995 | 1911 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2018 | 3473 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9621 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2011 | 1119 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4862 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8745 | 0.010 |
Why?
|
Social Class | 1 | 2011 | 2009 | 0.010 |
Why?
|
DNA | 1 | 1995 | 7214 | 0.010 |
Why?
|
Proteins | 1 | 1995 | 6011 | 0.010 |
Why?
|
Kidney | 1 | 1995 | 7057 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 1995 | 18366 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2013 | 5443 | 0.010 |
Why?
|
Mutation | 1 | 2020 | 30266 | 0.010 |
Why?
|
Infant, Newborn | 1 | 1995 | 26394 | 0.010 |
Why?
|
Pregnancy | 1 | 1995 | 30175 | 0.010 |
Why?
|
Animals | 1 | 1995 | 169408 | 0.000 |
Why?
|